C. David Weaver received his PhD in biological chemistry from the University of Tennessee at Knoxville in 1994 and performed postdoctoral studies in the Department of Pharmacology at Vanderbilt University.
Dr. Weaver joined the Bristol-Myers Squibb Company as an investigator in the Department of Neuroscience in 1997. In 1999 Dr. Weaver joined the Lead Discovery Department at Bristol Myers Squibb and was promoted to the rank of senior investigator. In 2004, he was recruited to Vanderbilt University as a Research Assistant Professor of Pharmacology and Assistant Director of the Molecular Recognition and Screening Facility. In this role he was responsible for the establishment and direction of a new high-throughput screening facility for Vanderbilt University through the Institute of Chemical Biology. In 2005 Dr. Weaver was promoted to Research Associate Professor, and was funded to direct one of the National Institutes of Health’s 10 national high-throughput screening centers.
Dr. Weaver serves on the editorial board of Assay Development and Drug Discovery. He has received numerous awards and honors, including the Bristol-Myers Squibb President’s Award and Pill Head Award for Scientific Innovation. Dr. Weaver’s current research is focused on development enabling technologies for translational biology and on development of novel treatment strategies for Parkinson’s disease, other brain disorders and type 2 diabetes/obesity.
Discovery of mGluR4 Potentiators for Symptoms & Side Effects and Disease-Modifying Treatment of PD